Health Minister Mark Butler has launched a federal parliamentary inquiry into the prescribing and sale of peptides, targeting a rapidly growing network of telehealth operators, online dispensaries and social media platforms that authorities say are making it dangerously easy for Australians to obtain unapproved drugs.

The investigation was requested in a letter to Labor MP and doctor Mike Freelander, chairman of the House of Representatives health committee, and signals a significant escalation in government scrutiny of Australia's booming digital healthcare economy.

What are peptides and why are regulators alarmed?

Peptides are substances increasingly promoted online for weight loss, muscle growth, faster recovery and anti-ageing. While they are used in some legitimate, approved medicines, regulators are concerned about a surge in unapproved preparations being marketed to consumers seeking rapid physical transformations.

The Therapeutic Goods Administration (TGA) has reported a sharp rise in the importation, compounding, supply and advertising of unapproved peptide products, driven in part by online prescribing services and promotion via social media. The Australian Medical Association has also flagged a growing number of cases involving people who sourced peptides through grey-market channels, often after encountering them on social platforms, and subsequently experienced serious side effects, hospitalisation or permanent health problems.

"I know peptides are often marketed on social media as wonder-drugs, but the reality is that they can pose serious health risks to Australian consumers," Butler said. "I am extremely concerned about escalating reports by the TGA of unapproved peptides being prescribed and delivered via telehealth and one-stop-shop style dispensaries."

Online business models under the microscope

A central focus of the inquiry will be vertically integrated healthcare businesses that control multiple stages of a patient's treatment, from initial consultation and prescribing through to dispensing and home delivery. Under this model, consumers can seek treatment, receive a prescription and have drugs delivered to their door without ever visiting a doctor in person.

Authorities acknowledge that such models can improve healthcare access, particularly for Australians in areas where seeing a doctor face-to-face is difficult. However, the inquiry will examine whether businesses that profit directly from selling treatments can genuinely provide independent clinical advice, and whether commercial incentives are driving inappropriate prescribing.

The terms of reference go beyond individual drug safety to ask whether Australia's regulatory and enforcement systems are equipped to keep pace with new models of online healthcare. The committee will also investigate prescribing patterns, the use of medicines outside their approved indications and the responsibilities of digital platforms in promoting peptide products to consumers.

Concern for young men targeted by social media influencers

Special Envoy for Men's Health and Labor MP Dan Repacholi said social media was awash with influencers promising bigger muscles, faster recovery and improved physiques, often without any disclosure of the health risks involved.

"But just because someone with a six-pack is promoting something online doesn't mean it's safe," Repacholi said. "I'm particularly concerned about young blokes being influenced by what they see online and turning to unapproved products without understanding the risks."

His comments reflect broader alarm about the influence of online fitness culture on health decision-making, with unregulated injectables being actively hyped by social media personalities to large and often young audiences.

What happens next

The House of Representatives health committee, led by Freelander, will now undertake the formal inquiry process, examining the full supply chain for peptide products as well as the adequacy of current consumer protections. The investigation is expected to consider whether legislative or regulatory changes are needed to bring online healthcare providers into line with the same standards applied to traditional medical practices.

The inquiry adds to mounting pressure on Australia's digital health sector to demonstrate that convenience and clinical safety can coexist, as regulators work to close the gaps that have allowed the unapproved peptide market to flourish.

Sponsored
Comparison of a Louis Vuitton perfume ($580) and Scent Room perfume ($85), highlighting price and branding differences.